Table 2 Therapy status at follow-up
Characteristic | All (n = 42) | Anti-IL-5 therapy responder (n = 32) | Anti-IL-5 therapy non-responder (n = 10) | p-value | |||
|---|---|---|---|---|---|---|---|
Anti-IL-5 therapy in month, median (IQR) | 12 | (7–15) | 12 | (8–15) | 9 | (6–12) | 0.146 |
Anti-IL-5 therapy response criteria, n (%) | |||||||
lung function (FEV1) | 26 | (62) | 26 | (81) | 0 | (0) | |
eosinophils | 39 | (93) | 31 | (97) | 8 | (80) | |
subjective condition | 32 | (76) | 32 | (100) | 0 | (0) | |
OCS therapy after anti-IL-5 therapy initiation | |||||||
Continuous OCS therapy at baseline – mg/d, median (IQR) | 5 | (5–10) | 5 | (5–10) | 5 | (5–12.5) | 0.821 |
Continuous OCS therapy at follow-up, mg/d, median (IQR) | 5 | (4–12.5) | 4.5 | (3.3–5) | 10 | (5–17.5) | 0.080 |
OCS therapy discontinued at follow-up, n (%) | 10 | (24) | 9 | (28) | 1 | (10) | 0.240 |